Transcutaneous Spinal Cord Stimulation to Stabilize Seated Systolic Blood Pressure in Persons With Chronic Spinal Cord Injury: Protocol Development.

IF 1.8 Q3 CLINICAL NEUROLOGY
Neurotrauma reports Pub Date : 2023-12-19 eCollection Date: 2023-01-01 DOI:10.1089/neur.2023.0063
Caitlyn G Peters, Noam Y Harel, Joseph P Weir, Yu-Kuang Wu, Lynda M Murray, Jorge Chavez, Fiona E Fox, Christopher P Cardozo, Jill M Wecht
{"title":"Transcutaneous Spinal Cord Stimulation to Stabilize Seated Systolic Blood Pressure in Persons With Chronic Spinal Cord Injury: Protocol Development.","authors":"Caitlyn G Peters, Noam Y Harel, Joseph P Weir, Yu-Kuang Wu, Lynda M Murray, Jorge Chavez, Fiona E Fox, Christopher P Cardozo, Jill M Wecht","doi":"10.1089/neur.2023.0063","DOIUrl":null,"url":null,"abstract":"<p><p>Transcutaneous spinal cord stimulation (tSCS) is an emerging therapeutic strategy to target spinal autonomic circuitry to normalize and stabilize blood pressure (BP) in hypotensive persons living with chronic spinal cord injury (SCI). Our aim is to describe our current methodological approach to identify individual tSCS parameters that result in the maintenance of seated systolic blood pressure (SBP) within a pre-defined target range. The parent study is a prospective, randomized clinical trial in which eligible participants will undergo multiple mapping sessions to optimize tSCS parameter settings to promote stable SBP within a target range of 110-120 mm Hg for males and 100-120 mm Hg for females. Parameter mapping includes cathode electrode placement site (T7/8, T9/10, T11/12, and L1/2), stimulation frequency (30, 60 Hz), current amplitudes (0-120 mA), waveform (mono- and biphasic), pulse width (1000 μs), and use of carrier frequency (0, 10 kHz). Each participant will undergo up to 10 mapping sessions involving different electrode placement sites and parameter settings. BP will be continuously monitored throughout each mapping session. Stimulation amplitude (mA) will be increased at intervals of between 2 and 10 mA until one of the following occurs: 1) seated SBP reaches the target range; 2) tSCS intensity reaches 120 mA; or 3) the participant requests to stop. Secondary outcomes recorded include 1) symptoms related to autonomic dysreflexia and orthostatic hypotension, 2) Likert pain scale, and 3) skin appearance after removal of the tSCS electrode. Clinical Trials Registration: NCT05180227.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"838-847"},"PeriodicalIF":1.8000,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10754346/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurotrauma reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/neur.2023.0063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Transcutaneous spinal cord stimulation (tSCS) is an emerging therapeutic strategy to target spinal autonomic circuitry to normalize and stabilize blood pressure (BP) in hypotensive persons living with chronic spinal cord injury (SCI). Our aim is to describe our current methodological approach to identify individual tSCS parameters that result in the maintenance of seated systolic blood pressure (SBP) within a pre-defined target range. The parent study is a prospective, randomized clinical trial in which eligible participants will undergo multiple mapping sessions to optimize tSCS parameter settings to promote stable SBP within a target range of 110-120 mm Hg for males and 100-120 mm Hg for females. Parameter mapping includes cathode electrode placement site (T7/8, T9/10, T11/12, and L1/2), stimulation frequency (30, 60 Hz), current amplitudes (0-120 mA), waveform (mono- and biphasic), pulse width (1000 μs), and use of carrier frequency (0, 10 kHz). Each participant will undergo up to 10 mapping sessions involving different electrode placement sites and parameter settings. BP will be continuously monitored throughout each mapping session. Stimulation amplitude (mA) will be increased at intervals of between 2 and 10 mA until one of the following occurs: 1) seated SBP reaches the target range; 2) tSCS intensity reaches 120 mA; or 3) the participant requests to stop. Secondary outcomes recorded include 1) symptoms related to autonomic dysreflexia and orthostatic hypotension, 2) Likert pain scale, and 3) skin appearance after removal of the tSCS electrode. Clinical Trials Registration: NCT05180227.

经皮脊髓刺激稳定慢性脊髓损伤患者的坐位收缩压:方案开发。
经皮脊髓刺激(tSCS)是一种新兴的治疗策略,它以脊髓自律神经回路为靶点,使慢性脊髓损伤(SCI)低血压患者的血压恢复正常并保持稳定。我们的目的是介绍我们目前采用的方法,以确定能将坐位收缩压(SBP)维持在预定目标范围内的各个 tSCS 参数。母研究是一项前瞻性随机临床试验,符合条件的参与者将接受多次测绘,以优化 tSCS 参数设置,从而促进 SBP 稳定在男性 110-120 mm Hg、女性 100-120 mm Hg 的目标范围内。参数映射包括阴极电极放置位置(T7/8、T9/10、T11/12 和 L1/2)、刺激频率(30、60 Hz)、电流幅度(0-120 mA)、波形(单相和双相)、脉冲宽度(1000 μs)和载波频率(0、10 kHz)的使用。每位受试者将接受多达 10 次不同电极放置位置和参数设置的映射治疗。每次绘图过程中都将持续监测血压。刺激振幅(毫安)将以 2 到 10 毫安的间隔增加,直到出现以下情况之一:1) 坐位 SBP 达到目标范围;2) tSCS 强度达到 120 mA;或 3) 参与者要求停止。记录的次要结果包括:1)与自主神经反射障碍和直立性低血压有关的症状;2)Likert 疼痛量表;3)移除 tSCS 电极后的皮肤外观。临床试验注册:NCT05180227。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信